Pretransplantation minimal residual disease monitoring by multiparameter flow cytometry predicts outcomes of AML patients receiving allogeneic hematopoietic stem cell transplantation.

导出 LinkOut

翻译打印收藏纠错

第一作者： Yun,Zhang

第一单位： Medical Center of Hematology, The Xinqiao Hospital of Army Medical University, Chongqing, China.

作者： Yun,Zhang ^[1] ; Ping,Wang ^[1] ; Kaniel,Cassady ^[2] ; Zhongmin,Zou ^[3] ; Yi,Li ^[1] ; Xiaojuan,Deng ^[1] ; Wuchen,Yang ^[1] ; Xiangui,Peng ^[4] ; Xi,Zhang ^[5] ; Yimei,Feng ^[6]

作者单位： Medical Center of Hematology, The Xinqiao Hospital of Army Medical University, Chongqing, China. ^[1] Regeneron Pharmaceuticals, Tarrytown, NY, United States. ^[2] Department of Chemical Defense Medicine, School of Military Preventive Medicine, Army Medical University, Chongqing, China. ^[3] Medical Center of Hematology, The Xinqiao Hospital of Army Medical University, Chongqing, China. Electronic address: 874214135@qq.com. ^[4] Medical Center of Hematology, The Xinqiao Hospital of Army Medical University, Chongqing, China. Electronic address: zhangxxi@sina.com. ^[5] Medical Center of Hematology, The Xinqiao Hospital of Army Medical University, Chongqing, China. Electronic address: yimeifeng@163.com. ^[6]

关键词 Acute myeloid leukemia/AML Allogeneic hemopoietic stem cell transplantation/allo-HSCT Haploidentical hematopoietic stem cell transplantations/haplo-HSCT Minimal residual disease/MRD Prognosis